Cormorant Asset Management Acquires Erasca Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Fool
- New Investment Position: Cormorant Asset Management disclosed a new position in Erasca on May 15, 2026, acquiring 5.8 million shares valued at approximately $68.55 million, indicating confidence in the company's clinical pipeline.
- Significant Holding: Erasca accounted for 4.71% of Cormorant's reportable assets in its 13F filing, highlighting the fund's recognition of Erasca's growth potential.
- Outstanding Stock Performance: As of May 14, 2026, Erasca's shares were priced at $10.37, reflecting a staggering 715% increase over the past year, significantly outperforming the S&P 500's 25% rise, which suggests positive market sentiment regarding its R&D progress.
- Strong Cash Position: Erasca ended the quarter with approximately $409 million in cash and marketable securities, expected to fund operations into the second half of 2028, indicating its potential in precision oncology despite currently having no approved products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 11.605
Low
2.00
Averages
5.50
High
11.00
Current: 11.605
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns regarding the company's compliance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 drug infringes on a patent and involves trade secret misappropriation, which could lead to increased legal liabilities.
- Stock Price Plummet Impact: Following the allegations, Erasca's stock price fell from $19.15 on April 27 to $9.90, a 48% drop, reflecting market pessimism about the company's future prospects.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact attorneys to discuss their legal rights, demonstrating the firm's commitment to protecting investor interests and its expertise in securities litigation.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its share price plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge regarding intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, severely impacting investor confidence.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's lead product candidate ERAS-0015, claiming patent infringement and demanding an immediate halt to its sales, which could inflict long-term damage on Erasca's market position.
- Investor Investigation Launched: In response to the severe market reaction, Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its ERAS-0015 intellectual property, potentially leading to further legal liabilities and financial losses.
- Uncertain Product Development Outlook: Erasca previously claimed that ERAS-0015 had a competitive edge over RevMed's RMC-6236, but the emergence of this legal challenge has cast doubt on the product's market prospects, potentially affecting future financing and research and development plans.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Cormorant Asset Management Acquires Erasca Shares
- New Investment Position: Cormorant Asset Management disclosed a new position in Erasca on May 15, 2026, acquiring 5.8 million shares valued at approximately $68.55 million, indicating confidence in the company's clinical pipeline.
- Significant Holding: Erasca accounted for 4.71% of Cormorant's reportable assets in its 13F filing, highlighting the fund's recognition of Erasca's growth potential.
- Outstanding Stock Performance: As of May 14, 2026, Erasca's shares were priced at $10.37, reflecting a staggering 715% increase over the past year, significantly outperforming the S&P 500's 25% rise, which suggests positive market sentiment regarding its R&D progress.
- Strong Cash Position: Erasca ended the quarter with approximately $409 million in cash and marketable securities, expected to fund operations into the second half of 2028, indicating its potential in precision oncology despite currently having no approved products.
See More
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns regarding the company's compliance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 drug infringes on a patent and involves trade secret misappropriation, which could lead to increased legal liabilities.
- Stock Price Plummet Impact: Following the allegations, Erasca's stock price fell from $19.15 on April 27 to $9.90, a 48% drop, reflecting market pessimism about the company's future prospects.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact attorneys to discuss their legal rights, demonstrating the firm's commitment to protecting investor interests and its expertise in securities litigation.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its share price plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge regarding intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, severely impacting investor confidence.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's lead product candidate ERAS-0015, claiming patent infringement and demanding an immediate halt to its sales, which could inflict long-term damage on Erasca's market position.
- Investor Investigation Launched: In response to the severe market reaction, Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its ERAS-0015 intellectual property, potentially leading to further legal liabilities and financial losses.
- Uncertain Product Development Outlook: Erasca previously claimed that ERAS-0015 had a competitive edge over RevMed's RMC-6236, but the emergence of this legal challenge has cast doubt on the product's market prospects, potentially affecting future financing and research and development plans.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Cormorant Asset Management Acquires Erasca Shares
- New Investment Position: Cormorant Asset Management disclosed a new position in Erasca on May 15, 2026, acquiring 5.8 million shares valued at approximately $68.55 million, indicating confidence in the company's clinical pipeline.
- Significant Holding: Erasca accounted for 4.71% of Cormorant's reportable assets in its 13F filing, highlighting the fund's recognition of Erasca's growth potential.
- Outstanding Stock Performance: As of May 14, 2026, Erasca's shares were priced at $10.37, reflecting a staggering 715% increase over the past year, significantly outperforming the S&P 500's 25% rise, which suggests positive market sentiment regarding its R&D progress.
- Strong Cash Position: Erasca ended the quarter with approximately $409 million in cash and marketable securities, expected to fund operations into the second half of 2028, indicating its potential in precision oncology despite currently having no approved products.
See More
